95 related articles for article (PubMed ID: 6125074)
1. Effect of betaxolol on heart rate at rest and during exercise.
Kesteloot H; Missotten A; Coupez-Lopinot R; Sluyts R
Acta Cardiol; 1982; 37(2):117-27. PubMed ID: 6125074
[TBL] [Abstract][Full Text] [Related]
2. Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.
Warrington SJ; Turner P; Kilborn JR; Bianchetti G; Morselli PL
Br J Clin Pharmacol; 1980 Nov; 10(5):449-52. PubMed ID: 6108127
[TBL] [Abstract][Full Text] [Related]
3. Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.
Balnave K; Neill JD; Russell CJ; Harron DW; Leahey WJ; Wilson R; Shanks RG
Br J Clin Pharmacol; 1981 Feb; 11(2):171-80. PubMed ID: 6111331
[TBL] [Abstract][Full Text] [Related]
4. Effects of betaxolol on heart rate in patients with a recent transmural myocardial infarction.
Yang XS; Coupez R; Ector H; Kesteloot H; De Geest H
Acta Cardiol; 1987; 42(4):273-86. PubMed ID: 2889303
[TBL] [Abstract][Full Text] [Related]
5. Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.
Giudicelli JF; Chauvin M; Thuillez C; Richer C; Bianchetti G; Gomeni R; Morselli PL
Br J Clin Pharmacol; 1980 Jul; 10(1):41-9. PubMed ID: 6104973
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.
Vinceneux P; Canal M; Domart Y; Roux A; Cascio B; Orofiamma B; Larribaud J; Flouvat B; Carbon C
Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):153-8. PubMed ID: 2870990
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.
Bianchetti G; Blatrix C; Gomeni R; Kilborn JR; Larribaud J; Lücker PW; Thebault JJ; Trocherie S; Morselli PL
Arzneimittelforschung; 1980; 30(11):1912-6. PubMed ID: 6109538
[TBL] [Abstract][Full Text] [Related]
8. The duration of effect of SL75212 on an exercise tachycardia [proceedings].
Balnave K; Neill JD; Russell CJ; Shanks RG; Leahey WJ; Wilson R; Harran DW
Br J Clin Pharmacol; 1980 Mar; 9(3):297P-298P. PubMed ID: 6102471
[No Abstract] [Full Text] [Related]
9. Effects of oral befunolol on heart rate and systolic blood pressure during submaximal exercise in man.
Miki N; Furusho Y; Itaya K; Midorikawa K; Kumagai E; Terasawa M; Ihara S; Matoba T; Toshima H
Jpn Circ J; 1980 Oct; 44(10):783-93. PubMed ID: 6107392
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers.
Cadigan PJ; London DR; Pentecost BL; Bianchetti G; Gomeni R; Kilborn JR; Morselli PL
Br J Clin Pharmacol; 1980 Jun; 9(6):569-75. PubMed ID: 6104498
[TBL] [Abstract][Full Text] [Related]
11. Effects of S-596, a new beta-adrenoceptor blocking agent on the left ventricular performance of normal subjects during exercise.
Nishida K; Niki S; Furukawa K; Yamada C; Sugihara H; Katsume H; Ijichi H
Jpn Heart J; 1985 May; 26(3):437-49. PubMed ID: 2411959
[TBL] [Abstract][Full Text] [Related]
12. The effect of a week's beta-adrenoceptor antagonism on daytime heart-rates, subjective responses to exercise, and physical activity in normal subjects.
Patrick JM; Wharrad HJ; Wilson CG; Birmingham AT
Br J Clin Pharmacol; 1985 Feb; 19(2):177-85. PubMed ID: 2859043
[TBL] [Abstract][Full Text] [Related]
13. Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension.
Beresford R; Heel RC
Drugs; 1986 Jan; 31(1):6-28. PubMed ID: 2866947
[TBL] [Abstract][Full Text] [Related]
14. Time course of the bronchial response to salbutamol after placebo, betaxolol and propranolol.
Palminteri R; Kaik G
Eur J Clin Pharmacol; 1983; 24(6):741-5. PubMed ID: 6136412
[TBL] [Abstract][Full Text] [Related]
15. A comparison between propranolol, practolol and betaxolol (SL75212) on the circulatory and metabolic responses to insulin-induced hypoglycaemia.
Saunders J; Gomeni R; Kilborn JR; Morselli PL; Sönksen PH
Eur J Clin Pharmacol; 1981; 21(3):177-84. PubMed ID: 6119203
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of a new beta-adrenoceptor blocking drug, befunolol. Cross-over comparison with propranolol on repeated administration.
Ebihara A; Tawara K; Oka T; Ofuji T; Kawahara K
Eur J Clin Pharmacol; 1982; 23(3):189-95. PubMed ID: 6129139
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of topical beta-blockers during exercise.
Atkins JM; Pugh BR; Timewell RM
Am J Ophthalmol; 1985 Feb; 99(2):173-5. PubMed ID: 3970121
[TBL] [Abstract][Full Text] [Related]
18. Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug.
Carruthers SG; Hosler JP; Pentikainen P; Azarnoff DL
Clin Pharmacol Ther; 1978 Aug; 24(2):168-74. PubMed ID: 28193
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the effect of a selective and a nonselective beta receptor blocker on the ischemic ST segment, lung function and stress-induced decrease in blood glucose].
Brügmann U; Blasini R
Herz; 1986 Feb; 11(1):55-61. PubMed ID: 2870014
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the duration of the effect of a single dose of nadolol on the product frequency x tension during exercise (author's transl)].
Donzeau JP; Birmacker A; Bernadet P; Bounhoure JP
Ann Cardiol Angeiol (Paris); 1978 Oct; 27(5):407-9. PubMed ID: 32825
[No Abstract] [Full Text] [Related]
[Next] [New Search]
